Waldenström macroglobulinemia treatment algorithm 2018

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Waldenström macroglobulinemia is often an indolent disorder, and many patients are candidates for observation with careful monitoring. For symptomatic patients, one must distinguish between those patients whose symptoms are related to immunologic manifestations associated with the IgM monoclonal protein and those that have symptoms related to progressive marrow and nodal infiltration with lymphoplasmacytic lymphoma. In Waldenström macroglobulinemia, the driver for therapy in the majority of patients is progressive anemia, secondary to bone marrow replacement by lymphoplasmacytic lymphoma. Recent introduction of MYD88 mutational analysis has been very useful for diagnostic purposes but is unclear what effect it might have on the prognosis or response rate to therapy. An algorithm is provided on the management of asymptomatic individuals and the sequence used for chemotherapeutic intervention of symptomatic patients.

Original languageEnglish (US)
Article number40
JournalBlood cancer journal
Issue number4
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Waldenström macroglobulinemia treatment algorithm 2018'. Together they form a unique fingerprint.

Cite this